Sanofi's sleeping sickness drug cures 95% of people in phase 2/3 trial, boosting plan to stop transmission

Sanofi’s oral sleeping sickness candidate acoziborole has achieved 95% efficacy in a late-phase clinical trial, delivering a boost to a global push to interrupt transmission of the parasitic disease by 2030.